Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rofecoxib vs Oxycodone/Acetaminophen for Postoperative Dental Pain
NCT00092326Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2002
- Primary completion
- Sep 2002
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of rofecoxib in odontalgia (3 arms), sponsored by Merck & Co. Primary endpoint: Post-op dental pain over 6 hours. Started Jun 2002; status: completed.
02
Drugs
rofecoxib
03
Conditions
odontalgia
Beyond the preview
Go deeper on NCT00092326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092326.